Semustine
From Wikipedia, the free encyclopedia
 |
The examples and perspective in this article may not represent a worldwide view of the subject. (May 2012) |
 |
|
|---|---|
| Systematic (IUPAC) name | |
| N-(2-Chloroethyl)-N'-(4-methylcyclohexyl)-N-nitrosourea | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 13909-09-6 |
| ATC code | L01AD03 |
| PubChem | CID 5198 |
| UNII | 6YY7T1T567  |
| KEGG | D05822 |
| Chemical data | |
| Formula | C10H18ClN3O2 |
| Mol. mass | 247.72 g/mol |
 (what is this?) (verify) |
|
Semustine is a drug used in chemotherapy.[1] It is structurally similar to lomustine, being distinguished from it only by an additional methyl group. It has been taken off the drug market for investigation of its cancerous effects, rated as IARC Group 1 carcinogen or a known carcinogen.[citation needed]
References [edit]
- ^ "Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group". Journal of clinical oncology : official journal of the American Society of Clinical Oncology 10 (4): 549–557. 1992. PMID 1548520.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
